How did Asia Pacific Dominate the Market in 2024?

In 2024, the Asia Pacific captured a dominant revenue share of the market share by 39%. A crucial driver is a growing tetanus and diphtheria prevalence, mainly in areas with inadequate vaccination rates, which is fostering the wider demand for vaccination programs. The TD vaccine market in ASAP is bolstering vaccine equity, escalating vaccine promise through community efforts, and optimising data collection for the detection of under-vaccinated populations. According to the WHO, in 2024, 92% of the infants in the ASAP received their third dose of the Diphtheria, Tetanus, and Pertussis (DTP) vaccine, a major global indicator of vaccination progress.

What Made Africa Dominant in the Market in 2024?

In the prospective period, Africa is predicted to expand at a rapid CAGR in the TD vaccine market. Primarily, the regional expansion will be propelled by robust government-led vaccination programs and policies, especially the Expanded Program on Immunisation in Nigeria and the National Immunisation Program in South Africa, which are further accelerating vaccine accessibility. A surge in the delivery of millions of vaccine doses by global health organisations, such as UNICEF, WHO, and Gavi, for supplemental immunisation activities (SIAs) is also impacting the overall progress. The WHO African Region (WHO AFRO) presented its DTP3 coverage rebound to 76% in 2024.

Segmental Insights

By product type analysis

Which Product Type Analysis Led the TD Vaccine Market in 2024?

The monovalent TD vaccines segment held a major share of the market in 2024. The increasing cases of tetanus and diphtheria, and government-led immunisation programs, are increasingly impacting the segmental growth. A promising step by the WHO is actively encouraging the shift from the single-antigen tetanus toxoid (TT) vaccine to the dual-antigen Td vaccine for adults and adolescents.

Eventually, the combination vaccines segment will register the fastest expansion. The segment will be driven by the convenience and affordability of offering multiple protections in a single dose, which enhances patient adherence and streamlines vaccination schedules. Nowadays, the globe is increasingly stepping into the use of hexavalent (6-in-1) vaccines for infants, which have a broader range of protection against diphtheria, tetanus, whole-cell or acellular pertussis (DTwP/DTaP), inactivated polio (IPV), Haemophilus influenzae type b (Hib), and Hepatitis B (HepB).

By age group analysis

How did the Adults & Adolescents Segment Dominate the Market in 2024?

In 2024, the adults & adolescents segment accounted for the biggest share of the TD vaccine market. Expanding awareness of vaccine-preventable diseases, government-funded immunization programs and global health encouragements, are fostering the segmental growth. Alongside, the rising need for booster doses for tetanus and diphtheria immunity, particularly during adolescence and throughout adulthood also bolstering the comprehensive growth.

However, the pregnant women segment will register the fastest growth during 2025-2034. The segment is increasingly fueled by a rise in government immunisation programs, particularly India's UIP, the high-risk nature of maternal tetanus, and the promotion of combination vaccines, such as Tdap, to offer widespread protection against whooping cough. Moreover, currently, the CDC and other advisory groups are widely encouraging the co-administration of inactivated vaccines, particularly Tdap, with other recommended maternal vaccines.

By end user analysis

Which End User Led the TD Vaccine Market in 2024?

The public health agencies segment accounted for the major share of the market in 2024. The phenomenal contribution of WHO, UNICEF, and GAVI is facilitating funding, logistical support, and vaccine distribution, specifically to emerging regions. In the current year, these agencies are highly focused on routine immunisation and supplementary activities for tetanus elimination, like vaccinating pregnant women with tetanus toxoid.

On the other hand, the travel clinics & military use segment is estimated to register rapid expansion during 2025-2034. Day by day, the globe is experiencing a huge rise in the need for boosters in international travel and deployment, which ensures consistent protection against tetanus and diphtheria for active personnel and travellers. Furthermore, these travel clinics are increasingly merging digital platforms to monitor patient immunisation status and send automated reminders for upcoming booster shots. Whereas military vaccine distribution propels advantages from "cold chain" optimisation, employing sophisticated logistics and IoT sensors to ensure vaccine integrity.

By distribution channel analysis

Why did the Government Supply Contracts/Immunization Programs Segment Dominate the Market in 2024?

The government supply contracts/immunization programs segment held a dominant share of the TD vaccine market in 2024. A prominent driver is the growth of mandatory national vaccination policies, international funding from organisations like UNICEF and WHO. Alongside, continuous alliances among governments, manufacturers, and international organizations, such as WHO and UNICEF are assisting to boost the overall vaccine supply chain, optimize effectiveness, and ensure availability.

Although the private distribution segment will expand rapidly in the coming era. Primarily, the increasing investment by numerous companies in R&D, manufacturing, and distribution partnerships is helping to raise availability and minimise expenses. Ongoing technological advancements in vaccine formulation, delivery systems, and supply chain efficiency make distribution robust and can enhance patient compliance. Along with this, the growing partnerships among pharmaceutical companies

Get the latest insights on life science industry segmentation with our Annual Membership:

By formulation analysis

Which Formulation Dominated the TD Vaccine Market in 2024?

In 2024, the single-dose vials/prefilled syringes segment accounted for the biggest share of the market. Mainly, the market players are emphasising patient safety, lowered vaccine waste, and enhanced convenience for both healthcare providers and recipients. Also, these formulations support minimising the risk of human handling errors and microbial contamination. The emergence of groundbreakings in syringe design, materials, and safety features, especially integrated safety devices, which make single-dose formats trustworthy and user-friendly.

On the other hand, the liquid (ready-to-use) form segment will expand at a rapid CAGR. Eventually, the market is leveraging those liquid formulations that are pre-mixed and ready for immediate use, which lowers preparation time and training for healthcare staff. Specifically, these impacts the reduction of the risk of microbial contamination that can arise during the handling and mixing of lyophilized (powder) vaccines. Additionally, the rising focus on the development of needle-free injectors and new cold chain management innovations accelerates the use of liquid vaccines.

What are Recent Developments in the TD Vaccine Market?

• In June 2025, Gujarat Health Minister Rushikesh Patel unveiled a state-level Td (Tetanus and Diphtheria) and DPT (Triple Antigen) immunisation campaign from Unjha in Mehsana district.
• In June 2025, the Edo State Government launched an emergency response to contain a diphtheria outbreak.

Browse More Insights of Towards Healthcare:

The consumption-type vaccine market

Similarly, the seasonal vaccines market

The global cell-based vaccine market

The veterinary vaccines market

The global vaccine adjuvant market

The global biological inactivated vaccine market

The Japan cell cancer vaccine market

The global viral vaccine cell culture media market

The global DNA vaccine market

The global influenza vaccine market

TD Vaccines Market Key Players List

• Sanofi Pasteur (Globally leading Td and Tdap manufacturer)
• GlaxoSmithKline (GSK)
• Serum Institute of India Pvt. Ltd.
• Biological E. Limited
• Bharat Biotech International Ltd.
• Panacea Biotec Ltd.
• Pfizer Inc. (through Tdap product – Adacel)
• Merck & Co., Inc.
• Emergent BioSolutions Inc.
• Microgen (Russia)
• PT Bio Farma (Indonesia)
• Chengdu Institute of Biological Products
• Sinovac Biotech Ltd.
• Haffkine Bio-Pharmaceutical Corporation Ltd.
• Vacsera (Egypt)
• LG Chem Ltd. (Korea)
• Novartis Vaccines (legacy – now part of GSK)
• Vabiotech (Vietnam)
• IMB Instituto Butantan (Brazil)
• WHO/UNICEF (as key procurement and policy stakeholders)

Download the Competitive Landscape market report @

Segments Covered in the Report

By Product Type

• Monovalent TD Vaccines
• Combination Vaccines
• TD + Pertussis (Tdap)
• TD + IPV (Polio)
• TD + Hib or Hepatitis B
  

By Age Group

• Adults & Adolescents
• Pediatrics
• Pregnant Women
  

By End User

• Public Health Agencies
• Hospitals & Clinics
• Private Vaccination Centres
• Travel Clinics & Military Use

By Distribution Channel

• Government Supply Contracts / Immunization Programs
• Private Distribution
• Non-Governmental Organisations
  

By Formulation

• Single-Dose Vials/Prefilled Syringes
• Multi-Dose Vials
• Freeze-Dried (Lyophilized) Form
• Liquid (Ready-to-use) Form

By Region

• North America
  • U.S.
  • Canada
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Thailand
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Sweden
  • Denmark
  • Norway
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa (MEA)
  • South Africa
  • UAE
  • Saudi Arabia
  • Kuwait
    

Immediate Delivery Available | Buy This Premium Research @

Access our exclusive, data-rich dashboard dedicated to the healthcare market - built specifically for decision-makers, strategists, and industry leaders. The dashboard features comprehensive statistical data, segment-wise market breakdowns, regional performance shares, detailed company profiles, annual updates, and much more. From market sizing to competitive intelligence, this powerful tool is one-stop solution to your gateway.

Access the Dashboard:

About Us

Towards Healthcare is a leading global provider of technological solutions, clinical research services, and advanced analytics, with a strong emphasis on life science research

You can place an order or ask any questions, please feel free to contact us at ...

Europe Region: +44 778 256 0738

North America Region: +1 8044 4193 44

APAC Region: +91 9356 9282 04

Web:

Our Trusted Data Partners

Precedence Research | Statifacts | Towards Packaging | Towards Automotive | Towards Food and Beverages | Towards Chemical and Materials | Towards Consumer Goods | Towards Dental | Towards EV Solutions | Nova One Advisor | Healthcare Webwire | Packaging Webwire | Automotive Webwire | Nutraceuticals Func Foods | Onco Quant | Sustainability Quant | Specialty Chemicals Analytics

Find us on social platforms: LinkedIn | Twitter | Instagram | Medium | Pinterest